A federal advisory panel voted Thursday to soften rules on seven peptides, including BPC-157 and TB-500. The vote was close. It is non-mandatory. The FDA has given no word on whether it will adopt the suggestion. The move came after weeks of community hearings. Wellness backers pressed firmly for wider access. RFK Jr. was among them. Critics say these compounds have little hard evidence of safety or help for most uses. The call could change how the agency handles a part of the wellness market that is growing very fast. Industry players are waiting to see if the FDA follows through on the vote. A spokesperson for the agency offered no clear schedule for a follow-up. Backers argue the change would broaden access to substances some say help. Opponents warn that looser rules could weaken safeguards across a barely regulated market. The panel vote only opens the door to a change, and the last word rests with the federal agency.